PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2004; 6(5): 197–202.
Published online Jul 29, 2004. doi:  10.1186/ar1222
PMCID: PMC546289
The current status of targeting BAFF/BLyS for autoimmune diseases
Meera Ramanujam1 and Anne Davidsoncorresponding author1
1Departments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA
corresponding authorCorresponding author.
Anne Davidson: davidson/at/aecom.yu.edu
Received April 13, 2004; Revisions requested July 6, 2004; Revised July 7, 2004; Accepted July 13, 2004.
Abstract
It is increasingly recognized that B cells have multiple functions that contribute to the pathogenesis of autoimmunity. Specific targeting of B cells might therefore be an appropriate therapeutic intervention. The tumor necrosis factor-like molecule BAFF (BLyS) is a key B cell survival factor and its receptors are expressed on most peripheral B cells. Several different BAFF antagonists are under development and in early clinical trials. We review here the rationale for BAFF blockade, and its predicted mechanism of action in autoimmune diseases.
Keywords: autoimmune diseases, B cells, BAFF (BLyS), co-stimulation, therapy
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central